Do you remember what the company paid for Eltoprazine?
Do you know what it's worth today?
Amarantus recently received an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million.
In all the posts about dilution, it's never mentioned that the assets are worth more today than 4 years ago. A lot more.